These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24028819)

  • 41. Fluorodeoxyglucose-PET/Computed Tomography-Guided Biopsy.
    Cerci JJ; Tabacchi E; Bogoni M
    PET Clin; 2016 Jan; 11(1):57-64. PubMed ID: 26590444
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in diagnosis and management of pancreatic cancer; comparison with multidetector row computed tomography, magnetic resonance imaging and endoscopic ultrasonography.
    Ergul N; Gundogan C; Tozlu M; Toprak H; Kadıoglu H; Aydin M; Cermik TF
    Rev Esp Med Nucl Imagen Mol; 2014; 33(3):159-64. PubMed ID: 24140024
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Role of fluorine 18 fluorodeoxyglucose positron emission tomography-computed tomography in focal and generalized infectious and inflammatory disorders.
    Haroon A; Zumla A; Bomanji J
    Clin Infect Dis; 2012 May; 54(9):1333-41. PubMed ID: 22431802
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [18F]Fluorodeoxyglucose PET for Interventional Oncology in Liver Malignancy.
    Samim M; El-Haddad GE; Molenaar IQ; Prevoo W; van den Bosch MA; Alavi A; Lam MG
    PET Clin; 2014 Oct; 9(4):469-95, vi. PubMed ID: 26050948
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Malignant disease as an incidental finding at ¹⁸F-FDG-PET/CT scanning in patients with granulomatous lung disease.
    Huber H; Hodolic M; Stelzmüller I; Wunn R; Hatzl M; Fellner F; Lamprecht B; Rubello D; Colletti PM; Gabriel M
    Nucl Med Commun; 2015 May; 36(5):430-7. PubMed ID: 25646704
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Functional imaging in extrapulmonary sarcoidosis: FDG-PET/CT and MR features.
    Soussan M; Augier A; Brillet PY; Weinmann P; Valeyre D
    Clin Nucl Med; 2014 Feb; 39(2):e146-59. PubMed ID: 23579973
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Detection of asymptomatic aortic involvement in ANCA-associated vasculitis using FDG PET/CT.
    Soussan M; Abad S; Mékinian A; Dhote R; Eder V
    Clin Exp Rheumatol; 2013; 31(1 Suppl 75):S56-8. PubMed ID: 23294518
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A role of FDG PET/CT for Response Assessment in Large Vessel Disease?
    Treglia G; Albano D; Dondi F; Bertagna F; Gheysens O
    Semin Nucl Med; 2023 Jan; 53(1):78-85. PubMed ID: 36075772
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Functional imaging of inflammatory diseases using nuclear medicine techniques.
    Basu S; Zhuang H; Torigian DA; Rosenbaum J; Chen W; Alavi A
    Semin Nucl Med; 2009 Mar; 39(2):124-45. PubMed ID: 19187805
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Positron emission tomography-computed tomography for imaging of inflammatory cardiovascular diseases.
    Miyagawa M; Yokoyama R; Nishiyama Y; Ogimoto A; Higaki J; Mochizuki T
    Circ J; 2014; 78(6):1302-10. PubMed ID: 24817762
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of FDG-PET and PET/CT in the diagnosis and management of vasculitis.
    Zerizer I; Tan K; Khan S; Barwick T; Marzola MC; Rubello D; Al-Nahhas A
    Eur J Radiol; 2010 Mar; 73(3):504-9. PubMed ID: 20172676
    [TBL] [Abstract][Full Text] [Related]  

  • 52. ¹⁸F-Fluorodeoxyglucose positron emission tomography/computed tomography finds answers in cancer patients with increasing tumor markers and negative or equivocal conventional imaging modalities.
    Salem SS; Shahin MA
    Nucl Med Commun; 2012 Mar; 33(3):313-21. PubMed ID: 22237387
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Vasculitis assessment with [18F]FDG positron emission tomography].
    Liozon E; Monteil J; Ly KH; Vidal E
    Rev Med Interne; 2010 Jun; 31(6):417-27. PubMed ID: 20416990
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The pivotal role of FDG-PET/CT in modern medicine.
    Hess S; Blomberg BA; Zhu HJ; Høilund-Carlsen PF; Alavi A
    Acad Radiol; 2014 Feb; 21(2):232-49. PubMed ID: 24439337
    [TBL] [Abstract][Full Text] [Related]  

  • 55. FDG PET for gauging of sarcoid disease activity.
    Adams H; Keijsers RG; Korenromp IH; Grutters JC
    Semin Respir Crit Care Med; 2014 Jun; 35(3):352-61. PubMed ID: 25007087
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [(18)F]fluorodeoxyglucose PET in large vessel vasculitis.
    Walter MA
    Radiol Clin North Am; 2007 Jul; 45(4):735-44, viii. PubMed ID: 17706537
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nodular nongranulomatous vasculitis of the lung detected by 18F-FDG PET/CT.
    Treglia G; Collarino A; Lago M; Rindi G; Giordano A
    Clin Nucl Med; 2013 Mar; 38(3):e148-51. PubMed ID: 23354025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Phase analysis by gated F-18 FDG PET/CT for left ventricular dyssynchrony assessment: a comparison with gated Tc-99m sestamibi SPECT.
    Wang L; Wei HX; Yang MF; Guo J; Wang JF; Fang W; Wang YT
    Ann Nucl Med; 2013 May; 27(4):325-34. PubMed ID: 23371445
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of positron emission tomography-computed tomography/magnetic resonance imaging in the management of sarcoidosis patients.
    Promteangtrong C; Salavati A; Cheng G; Torigian DA; Alavi A
    Hell J Nucl Med; 2014; 17(2):123-35. PubMed ID: 25097898
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Efficacy of heparin loading during an 18F-FDG PET/CT examination to search for cardiac sarcoidosis activity.
    Ito K; Morooka M; Okazaki O; Minaminoto R; Kubota K; Hiroe M
    Clin Nucl Med; 2013 Feb; 38(2):128-30. PubMed ID: 23334129
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.